Rubicon Research's TEAM
We have a team of highly dedicated, experienced and knowledgeable formulation and analytical chemists with a proven track record in developing pulmonary and nasal drug products.
Impopharma Canada Ltd. is a Toronto, Canada-based developer of pharmaceutical products and complex formulations focused on inhalation pharmaceutical products (solution and suspension sprays, pMDI and DPI).
Impopharma Inc. was founded in 1996 as a CRO by Hanna Piskorz and Harold Wulffhart in a single office enterprise of ~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft² comprised of laboratory, small pilot manufacturing, document storage, sample storage and office space operating within an FDA and Health inspected QMS. In October 2018, Impopharma Inc. was acquired by OBG Pharma Group, the Canadian subsidiary was renamed Impopharma Canada Ltd.
Over the years, Impopharma has acted as an extension of the client’s laboratory, including Top 20 global Rx pharma companies, and has equipped itself with highly specialized equipment, key scientists as well as expertise in many product development strategies in line with current regulatory expectations.